New Risk • May 28
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 15% Last year net profit margin: 25% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (15% net profit margin). Valuation Update With 7 Day Price Move • May 26
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₩6,100, the stock trades at a trailing P/E ratio of 25x. Average trailing P/E is 21x in the Medical Equipment industry in South Korea. Total loss to shareholders of 2.2% over the past three years. Tillkännagivande • Mar 10
Bio Plus Co., Ltd, Annual General Meeting, Mar 30, 2026 Bio Plus Co., Ltd, Annual General Meeting, Mar 30, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 8, dunchon-daero 457beon-gil, jungwon-gu, gyeonggi-do, seongnam South Korea Valuation Update With 7 Day Price Move • Mar 04
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ₩4,550, the stock trades at a trailing P/E ratio of 17.4x. Average trailing P/E is 19x in the Medical Equipment industry in South Korea. Total loss to shareholders of 35% over the past three years. New Risk • Feb 26
New minor risk - Dividend sustainability The dividend is not well covered by cash flows. The company is paying a dividend despite having no free cash flows. Dividend yield: 1.0% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (36% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (17% net profit margin). Upcoming Dividend • Dec 22
Upcoming dividend of ₩50.00 per share Eligible shareholders must have bought the stock before 29 December 2025. Payment date: 13 April 2026. Payout ratio is a comfortable 18% but the company is not cash flow positive. Trailing yield: 0.9%. Lower than top quartile of South Korean dividend payers (3.6%). Lower than average of industry peers (1.1%). Declared Dividend • Nov 08
Dividend of ₩50.00 announced Dividend of ₩50.00 is the same as last year. Ex-date: 29th December 2025 Payment date: 13th April 2026 Dividend yield will be 0.8%, which is lower than the industry average of 1.8%. Sustainability & Growth Dividend is covered by earnings (18% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has decreased over the past 36 years, indicating a lack of growth and stability in payments. Earnings per share has grown by 13% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. Tillkännagivande • Nov 07
Bio Plus Co., Ltd announces Annual dividend, payable on April 13, 2026 Bio Plus Co., Ltd announced Annual dividend of KRW 50.0000 per share payable on April 13, 2026, ex-date on December 29, 2025 and record date on December 31, 2025. Valuation Update With 7 Day Price Move • Sep 16
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₩7,200, the stock trades at a trailing P/E ratio of 26.2x. Average trailing P/E is 24x in the Medical Equipment industry in South Korea. Total loss to shareholders of 9.0% over the past three years. New Risk • Sep 01
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 18% Last year net profit margin: 37% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (47% accrual ratio). Minor Risk Profit margins are more than 30% lower than last year (18% net profit margin). Valuation Update With 7 Day Price Move • Apr 14
Investor sentiment improves as stock rises 23% After last week's 23% share price gain to ₩8,020, the stock trades at a trailing P/E ratio of 32.9x. Average trailing P/E is 15x in the Medical Equipment industry in South Korea. Total returns to shareholders of 8.8% over the past three years. New Risk • Mar 30
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 21% Last year net profit margin: 39% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (68% accrual ratio). Minor Risk Profit margins are more than 30% lower than last year (21% net profit margin). Tillkännagivande • Feb 28
Bio Plus Co., Ltd, Annual General Meeting, Mar 28, 2025 Bio Plus Co., Ltd, Annual General Meeting, Mar 28, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 8, dunchon-daero 457beon-gil, jungwon-gu, gyeonggi-do, seongnam South Korea Valuation Update With 7 Day Price Move • Feb 17
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₩7,170, the stock trades at a trailing P/E ratio of 23.1x. Average trailing P/E is 19x in the Medical Equipment industry in South Korea. Total returns to shareholders of 16% over the past three years. Upcoming Dividend • Dec 20
Upcoming dividend of ₩70.00 per share Eligible shareholders must have bought the stock before 27 December 2024. Payment date: 09 April 2025. Payout ratio is a comfortable 22% but the company is not cash flow positive. Trailing yield: 0.9%. Lower than top quartile of South Korean dividend payers (3.9%). Lower than average of industry peers (1.4%). Valuation Update With 7 Day Price Move • Dec 12
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₩6,880, the stock trades at a trailing P/E ratio of 21.8x. Average trailing P/E is 13x in the Medical Equipment industry in South Korea. Total returns to shareholders of 11% over the past three years. New Risk • Dec 11
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (69% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (9.3% average weekly change). Valuation Update With 7 Day Price Move • Nov 14
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to ₩4,560, the stock trades at a trailing P/E ratio of 13x. Average trailing P/E is 12x in the Medical Equipment industry in South Korea. Total loss to shareholders of 21% over the past three years. Tillkännagivande • Aug 02
Bio Plus Co., Ltd announced that it has received KRW 60 billion in funding On July 31, 2024, Bio Plus Co., Ltd, closed the transaction. New Risk • Jul 24
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (54% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.2% average weekly change). Valuation Update With 7 Day Price Move • Jul 05
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₩6,450, the stock trades at a trailing P/E ratio of 16.9x. Average trailing P/E is 16x in the Medical Equipment industry in South Korea. Total loss to shareholders of 4.3% over the past year. Tillkännagivande • Jun 11
Bio Plus Co., Ltd (KOSDAQ:A099430) announces an Equity Buyback for KRW 5,000 million worth of its shares. Bio Plus Co., Ltd (KOSDAQ:A099430) announces a share repurchase program. Under the program, the company will repurchase up to KRW 5,000 million worth of its shares, pursuant to a contract with Korea Investment & Securities Co.,Ltd. The purpose of the program is to stabilize stock price and to enhance the shareholder value. The program will expire on December 10, 2024. As of June 9, 2024, the company had 743,436 shares in treasury within scope available for dividend and had no shares in treasury under other capacities. Buy Or Sell Opportunity • Jun 10
Now 22% overvalued Over the last 90 days, the stock has fallen 33% to ₩4,580. The fair value is estimated to be ₩3,756, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 26% over the last 3 years. Earnings per share has grown by 25%. Valuation Update With 7 Day Price Move • May 17
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to ₩5,180, the stock trades at a trailing P/E ratio of 11.6x. Average trailing P/E is 18x in the Medical Equipment industry in South Korea. Total loss to shareholders of 19% over the past year. Reported Earnings • Mar 24
Full year 2023 earnings released: EPS: ₩445 (vs ₩372 in FY 2022) Full year 2023 results: EPS: ₩445 (up from ₩372 in FY 2022). Revenue: ₩65.0b (up 15% from FY 2022). Net income: ₩25.6b (up 21% from FY 2022). Profit margin: 39% (up from 37% in FY 2022). The increase in margin was driven by higher revenue. Upcoming Dividend • Dec 20
Upcoming dividend of ₩70.00 per share at 1.0% yield Eligible shareholders must have bought the stock before 27 December 2023. Payment date: 10 April 2024. Payout ratio is a comfortable 16% and this is well supported by cash flows. Trailing yield: 1.0%. Lower than top quartile of South Korean dividend payers (3.5%). Lower than average of industry peers (1.6%). Buying Opportunity • Oct 19
Now 22% undervalued after recent price drop Over the last 90 days, the stock is down 19%. The fair value is estimated to be ₩8,126, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 37% over the last year. Earnings per share has grown by 92%. Revenue is forecast to grow by 84% in 2 years. Earnings is forecast to grow by 63% in the next 2 years. Valuation Update With 7 Day Price Move • Aug 16
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₩8,870, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 15x in the Medical Equipment industry in South Korea. Total returns to shareholders of 11% over the past year. Simply Wall St's valuation model estimates the intrinsic value at ₩7,559 per share. Valuation Update With 7 Day Price Move • Jun 20
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₩7,370, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 14x in the Medical Equipment industry in South Korea. Total returns to shareholders of 12% over the past year. Simply Wall St's valuation model estimates the intrinsic value at ₩4,098 per share. Valuation Update With 7 Day Price Move • Jan 25
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₩8,550, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 12x in the Medical Equipment industry in South Korea. Total returns to shareholders of 54% over the past year. Simply Wall St's valuation model estimates the intrinsic value at ₩11,285 per share. Price Target Changed • Dec 15
Price target increased to ₩9,750 Up from ₩8,917, the current price target is an average from 3 analysts. New target price is 33% above last closing price of ₩7,330. Stock is up 16% over the past year. The company is forecast to post earnings per share of ₩362 for next year compared to ₩207 last year. Price Target Changed • Nov 16
Price target increased to ₩38,500 Up from ₩35,667, the current price target is an average from 2 analysts. New target price is 34% above last closing price of ₩28,700. Stock is up 18% over the past year. The company is forecast to post earnings per share of ₩1,493 for next year compared to ₩828 last year. Valuation Update With 7 Day Price Move • Nov 07
Investor sentiment improved over the past week After last week's 16% share price gain to ₩31,100, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 10x in the Medical Equipment industry in South Korea. Total returns to shareholders of 29% over the past year. Simply Wall St's valuation model estimates the intrinsic value at ₩46,800 per share. Price Target Changed • Nov 02
Price target increased to ₩38,500 Up from ₩35,667, the current price target is an average from 2 analysts. New target price is 44% above last closing price of ₩26,750. Stock is down 0.6% over the past year. The company is forecast to post earnings per share of ₩1,493 for next year compared to ₩828 last year. Valuation Update With 7 Day Price Move • Oct 13
Investor sentiment deteriorated over the past week After last week's 18% share price decline to ₩24,800, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 10x in the Medical Equipment industry in South Korea. Total loss to shareholders of 5.3% over the past year. Simply Wall St's valuation model estimates the intrinsic value at ₩40,006 per share. Tillkännagivande • Oct 07
BioPlus Co., Ltd. announced that it expects to receive KRW 19.99996275 billion in funding BioPlus Co., Ltd. announced a private placement of 690,845 registered non-voting redeemable convertible preferred shares at issue price of KRW 28,950 per share for gross proceeds of KRW 19,999,962,750? on October 6, 2022. The transaction will include participation from Lindman - Woori Technology Finance Fund No. 13 for 69,084 shares, Lindman Innovation Growth Private Equity Joint Venture for 345,423 shares, and Lindman Asia Fund No. 16 for 276,338 shares. The shares carry rate of interest of 10% per annum. The shares to be issued shall have a hold period of 1 year from the closing of the transaction. The repayment period is from April 25, 2025 to October 24, 2032. The shares are convertible into 690,845 shares of the company from January 25, 2023 to October 24, 2032. The transaction is expected to close on October 24, 2022. The transaction has been approved by the board of directors of the company. Valuation Update With 7 Day Price Move • Jul 07
Investor sentiment improved over the past week After last week's 16% share price gain to ₩28,450, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 11x in the Medical Equipment industry in South Korea. Simply Wall St's valuation model estimates the intrinsic value at ₩43,793 per share.